Journal article · 2025 · Open access

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

Lingying Wu, Jing Wang, Qingshui Li, Danbo Wang, Cuiying Zhang, Junying Tang, Guonan Zhang, Min Hao, Desheng Yao, Qinglei Gao, Youzhong Zhang, Ruifang An and 45 more

CA A Cancer Journal for Clinicians, 76(1), e70042 · Published 25 November 2025 · DOI 10.3322/caac.70042

Open PDFView at the publisherCite this paper

In brief

“Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial” is a 2025 journal article by Lingying Wu and 56 co-authors, published in CA A Cancer Journal for Clinicians. OpenAlex counts 18 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at CA A Cancer Journal for Clinicians.

Citations
18
Most cited in
2026 (17)
Field-weighted impact
5.53
References
30
Authors
57

Abstract

Although poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first-line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA-mutated/homologous recombination-deficient (HRD) patients, is lacking. This study compared combined fuzuloparib (a PARPi) plus apatinib (a vascular endothelial growth factor receptor-2 inhibitor) with either fuzuloparib or placebo as first-line maintenance in patients with advanced OC. Patients who had newly diagnosed, advanced OC and responded to first-line, platinum-based chemotherapy were randomized 2:2:1 to receive combined fuzuloparib (100 mg twice daily) plus apatinib (375 mg daily), fuzuloparib (150 mg twice daily) plus placebo, or double-placebo treatment. The primary end point was blinded independent review committee (BIRC)-assessed progression-free survival (PFS). Six hundred seventy-four patients were randomized to receive fuzuloparib plus apatinib (n = 269), fuzuloparib (n = 269), or placebo (n = 136). At the final analysis (November 1, 2024; 385 BIRC-assessed PFS events; median follow-up, 40 months), the median BIRC-assessed PFS was 26.9 months with the combination versus placebo (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.44-0.75; one-sided p < .0001) and 29.9 months with fuzuloparib monotherapy versus placebo (HR, 0.58; 95% CI, 0.44-0.75; one-sided p < .0001) compared with 11.1 months with placebo. A PFS benefit was observed regardless of germline BRCA1/2 mutation status. In homologous recombination-deficient patients (including those with BRCA1/2 mutations), combined fuzuloparib and apatinib produced a PFS similar to that of fuzuloparib (34.1 vs. 35.8 months, respectively); in homologous recombination-proficient patients, PFS had a trend favoring the combination (16.6 vs. 11.0 months; HR, 0.73; 95% CI, 0.45-1.19). Both treatments were well tolerated. Overall survival was immature. Both fuzuloparib and combination therapy improved PFS compared with placebo as maintenance therapy for patients who had newly diagnosed, advanced OC. Adding apatinib to fuzuloparib did not prolong PFS among homologous recombination-deficient patients. There was a PFS benefit trend among homologous recombination-proficient patients who received combination therapy compared with those who received monotherapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wu, L., Wang, J., Li, Q., Wang, D., Zhang, C., Tang, J., Zhang, G., Hao, M., Yao, D., Gao, Q., Zhang, Y., An, R., Yin, R., Wang, L., Xia, B., Zhou, Q., Yang, H., Zhu, J., Jiang, K., . . . Li, N. (2025). Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial. CA A Cancer Journal for Clinicians, 76(1), e70042. https://doi.org/10.3322/caac.70042

MLA 9

Wu, Lingying, et al. “Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial.” CA A Cancer Journal for Clinicians, vol. 76, no. 1, 2025, p. e70042. https://doi.org/10.3322/caac.70042.

Chicago

Wu, Lingying, Jing Wang, Qingshui Li, Danbo Wang, Cuiying Zhang, Junying Tang, Guonan Zhang, et al. 2025. “Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial.” CA A Cancer Journal for Clinicians 76 (1): e70042. https://doi.org/10.3322/caac.70042.

Harvard

Wu, L. et al. (2025) ‘Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial’, CA A Cancer Journal for Clinicians, 76(1), p. e70042. doi:10.3322/caac.70042.

IEEE

L. Wu et al., “Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial,” CA A Cancer Journal for Clinicians, vol. 76, no. 1, p. e70042, 2025, doi: 10.3322/caac.70042.

BibTeX

@article{wu2025fuzuloparib,
  title     = {{Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial}},
  author    = {Wu, Lingying and Wang, Jing and Li, Qingshui and Wang, Danbo and Zhang, Cuiying and Tang, Junying and Zhang, Guonan and Hao, Min and Yao, Desheng and Gao, Qinglei and Zhang, Youzhong and An, Ruifang and Yin, Rutie and Wang, Li and Xia, Bairong and Zhou, Qi and Yang, Hongying and Zhu, Jianqing and Jiang, Kui and Chen, Zhengzheng and Wu, Qiang and Duan, Wei Jia and Huang, Yi and Zhang, Hui and Wei, Shuqing and Li, Guiling and Meng, Yuanguang and Wang, Ke and Yang, Xinfeng and Huang, Xianghua and others},
  journal   = {CA A Cancer Journal for Clinicians},
  year      = {2025},
  volume    = {76},
  number    = {1},
  pages     = {e70042},
  doi       = {10.3322/caac.70042},
  url       = {https://doi.org/10.3322/caac.70042}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy

  • apatinib
  • advanced ovarian cancer
  • maintenance therapy
  • PARP inhibitors
  • VEGFR-2 inhibitors
  • progression-free survival
  • BRCA mutations
  • homologous recombination deficiency

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Wu, L., Wang, J., Li, Q., Wang, D., Zhang, C., Tang, J., Zhang, G., Hao, M., Yao, D., Gao, Q., Zhang, Y., An, R., Yin, R., Wang, L., Xia, B., Zhou, Q., Yang, H., Zhu, J., Jiang, K., . . . Li, N. (2025). Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial. CA A Cancer Journal for Clinicians, 76(1), e70042. https://doi.org/10.3322/caac.70042

How many times has this paper been cited?

18 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at CA A Cancer Journal for Clinicians: sign in and open the PDF from this page.

Who wrote this paper?

Lingying Wu, Jing Wang, Qingshui Li, Danbo Wang, Cuiying Zhang, Junying Tang, Guonan Zhang, Min Hao, Desheng Yao, Qinglei Gao, Youzhong Zhang, Ruifang An and 45 more.

What is the DOI of this paper?

10.3322/caac.70042, permanently at https://doi.org/10.3322/caac.70042. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.